Dimensional Fund Advisors LP Has $910,000 Stock Holdings in Rezolute, Inc. (NASDAQ:RZLT)

Dimensional Fund Advisors LP raised its position in Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 222.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 185,768 shares of the company's stock after purchasing an additional 128,190 shares during the quarter. Dimensional Fund Advisors LP owned 0.32% of Rezolute worth $910,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new stake in Rezolute in the 3rd quarter valued at approximately $42,000. Charles Schwab Investment Management Inc. lifted its position in shares of Rezolute by 65.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock worth $112,000 after purchasing an additional 9,000 shares in the last quarter. ExodusPoint Capital Management LP acquired a new position in Rezolute during the fourth quarter worth $277,000. Barclays PLC acquired a new position in Rezolute during the fourth quarter worth $314,000. Finally, American Century Companies Inc. increased its stake in Rezolute by 62.1% in the 4th quarter. American Century Companies Inc. now owns 64,591 shares of the company's stock valued at $316,000 after buying an additional 24,742 shares during the last quarter. 82.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Guggenheim restated a "buy" rating on shares of Rezolute in a research note on Monday, February 10th. Wedbush reaffirmed an "outperform" rating and set a $12.00 price target on shares of Rezolute in a research report on Wednesday, May 14th. Craig Hallum upgraded Rezolute to a "strong-buy" rating in a research note on Tuesday, February 4th. HC Wainwright reissued a "buy" rating and issued a $14.00 target price on shares of Rezolute in a research note on Monday, April 28th. Finally, JMP Securities boosted their target price on shares of Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a report on Thursday, February 13th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Rezolute has a consensus rating of "Buy" and a consensus target price of $12.14.

Rezolute Stock Performance

NASDAQ RZLT opened at $4.01 on Thursday. Rezolute, Inc. has a 52-week low of $2.22 and a 52-week high of $6.19. The stock has a market cap of $242.75 million, a PE ratio of -3.29 and a beta of 1.01. The firm has a 50-day moving average of $3.25 and a 200-day moving average of $4.28.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). As a group, analysts predict that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Insider Activity

In related news, CEO Nevan C. Elam purchased 12,302 shares of the company's stock in a transaction that occurred on Thursday, March 27th. The stock was acquired at an average price of $2.85 per share, with a total value of $35,060.70. Following the completion of the purchase, the chief executive officer now directly owns 224,119 shares in the company, valued at $638,739.15. This trade represents a 5.81% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Daron Evans acquired 10,000 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The shares were purchased at an average cost of $2.89 per share, with a total value of $28,900.00. Following the transaction, the chief financial officer now directly owns 237,900 shares of the company's stock, valued at $687,531. This trade represents a 4.39% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 29,060 shares of company stock valued at $83,694. 18.39% of the stock is owned by company insiders.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.